Pages that link to "Q39680805"

The following pages link to Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells (Q39680805):

Displaying 13 items.

• Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton (Q28538172) (← links)
• Modulation of the myxoma virus plaque phenotype by vaccinia virus protein F11. (Q30524111) (← links)
• A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice (Q30938741) (← links)
• Smallpox vaccines: targets of protective immunity (Q34780607) (← links)
• Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants (Q37209483) (← links)
• The strategic use of novel smallpox vaccines in the post-eradication world (Q37909421) (← links)
• Remodeling of the fibroblast cytoskeletal architecture during the replication cycle of Ectromelia virus: A morphological in vitro study in a murine cell line (Q38771653) (← links)
• TRAF2 facilitates vaccinia virus replication by promoting rapid virus entry (Q38854837) (← links)
• Vaccinia virus F5 is required for normal plaque morphology in multiple cell lines but not replication in culture or virulence in mice (Q38989113) (← links)
• Small rho GTPases and cholesterol biosynthetic pathway intermediates in African swine fever virus infection. (Q40304842) (← links)
• Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions (Q42108903) (← links)
• Initial characterization of vaccinia virus B4 suggests a role in virus spread (Q42212627) (← links)
• SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells (Q92404259) (← links)